GLP-1 and Health Conditions: PCOS, Heart, Sleep Apnea

GLP-1 medications were developed for type 2 diabetes. That is still where most of the clinical trial data originated. But over the past several years, landmark trials have documented effects that go well beyond blood sugar and weight. If you have an underlying health condition, the research on GLP-1 medications may be more relevant to your situation than you expect.

This section summarizes what the clinical evidence shows for specific conditions: PCOS, sleep apnea, cardiovascular disease, kidney disease, fatty liver disease, and metabolic syndrome. It is organized to help you understand what has been studied, in which populations, and what the current evidence says.

One important clarification before we start.

A note on branded medications vs. compounded formulations

Every clinical trial discussed on this page was conducted using FDA-approved brand-name GLP-1 medications: semaglutide (prescribed for type 2 diabetes or for weight management) or tirzepatide (prescribed for type 2 diabetes or for weight management). The findings from those trials apply to the specific medications tested.

Compounded semaglutide and compounded tirzepatide are not FDA-approved products. They have not been independently evaluated by the FDA for safety, efficacy, or quality. The clinical findings documented in these trials cannot be directly assumed to apply to compounded formulations.

This does not mean compounded medications are ineffective. It means the specific trial data discussed here is evidence about the branded drugs tested, not a blanket statement about any product containing the same active ingredient. Your provider will help you understand what the evidence means for your specific situation and formulation.

This disclosure applies to every condition discussed below.

PCOS: where GLP-1 biology and hormonal health intersect

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age. Insulin resistance is a core mechanism in most cases of PCOS, not a side effect of it. The elevated insulin levels that result from insulin resistance drive the excess androgen production, disrupted ovulation, and metabolic dysfunction that define the condition.

GLP-1 medications work in part by improving insulin sensitivity. The hypothalamus responds differently when GLP-1 is present. Insulin levels fall. That is relevant to PCOS in a direct way.

A 2023 meta-analysis published in Obesity Reviews examined the use of GLP-1 receptor agonists in PCOS populations across multiple clinical trials. The analysis found improvements in:

• Body weight and BMI
• Insulin resistance markers (fasting insulin, HOMA-IR)
• Menstrual regularity
• Androgen levels (testosterone, free androgen index)

These are not small effects. For women with PCOS who have insulin resistance at the core of their symptoms, GLP-1 treatment addresses the underlying mechanism rather than just managing surface symptoms.

This is particularly relevant to our primary patient population. Many perimenopausal women have PCOS or carry undiagnosed insulin resistance that has worsened with hormonal changes. If your provider has mentioned blood sugar trends, metabolic syndrome, or PCOS, GLP-1 treatment may be addressing more than one problem simultaneously. Read more: GLP-1 and PCOS: Insulin Resistance, Hormones, and Weight Loss.

Sleep apnea: the SURMOUNT-OSA trial

Obstructive sleep apnea (OSA) in people with obesity is driven, at least in part, by excess fat tissue around the upper airway that physically narrows the breathing passage during sleep. Weight loss – of any cause – tends to improve OSA severity.

The SURMOUNT-OSA trial tested this hypothesis in a rigorous way. It enrolled adults with moderate-to-severe obesity-related obstructive sleep apnea and randomized them to tirzepatide prescribed for weight management or placebo. The primary measure was the apnea-hypopnea index (AHI), which counts the number of breathing disruptions per hour of sleep.

The trial found significant reductions in AHI in the tirzepatide group, with many participants moving from severe or moderate OSA into the mild or resolved category. The FDA approved this indication in 2024.

For patients with sleep apnea who have been told they need to lose weight to improve their breathing, this evidence is directly relevant. Read more: GLP-1 and Sleep Apnea.

Cardiovascular disease: the SELECT trial

The SELECT trial is one of the most important cardiovascular outcomes studies in recent memory. Published in the New England Journal of Medicine in 2023, it enrolled over 17,000 adults with obesity or overweight and established cardiovascular disease – defined as prior heart attack, stroke, or peripheral artery disease – but without type 2 diabetes.

The trial tested semaglutide prescribed for weight management against placebo and tracked major cardiovascular events over roughly 3.5 years.

The result: a 20% reduction in the combined rate of cardiovascular death, non-fatal heart attack, and non-fatal stroke in the semaglutide group compared to placebo.

This was the first large trial to demonstrate this kind of cardiovascular benefit in a non-diabetic obesity population. The implication is significant: the benefit appears to extend beyond glycemic control and may reflect the broader metabolic and anti-inflammatory effects of GLP-1 signaling.

For patients who have already had a heart attack or stroke, or who have been told they are at elevated cardiovascular risk, this trial is worth understanding in detail. Read more: GLP-1 and Cardiovascular Health.

Kidney disease: the FLOW trial

The FLOW trial (Evaluate Renal Function with Semaglutide Use in People with Type 2 Diabetes), published in the New England Journal of Medicine in 2024, enrolled patients with type 2 diabetes and chronic kidney disease. It tested semaglutide prescribed for type 2 diabetes against placebo and tracked kidney outcomes over approximately three years.

The trial was stopped early because the benefit was so clear. Semaglutide significantly reduced:

• Worsening kidney function (sustained 50% or greater decline in eGFR)
• The need for kidney replacement therapy (dialysis or transplant)
• Death from kidney causes
• Death from cardiovascular causes

CKD progression is one of the most difficult problems in metabolic medicine. The FLOW findings suggest that GLP-1 treatment may slow that progression in patients with type 2 diabetes and CKD, which are two conditions that very commonly occur together.

For patients with existing kidney disease, this data is important to discuss with your provider. Read more: GLP-1 and Kidney Health: FLOW Trial.

Fatty liver disease: MASH and NAFLD

Metabolic-associated steatohepatitis (MASH, formerly called NASH or non-alcoholic steatohepatitis) is a progressive liver disease driven by fat accumulation and inflammation. It is closely tied to insulin resistance and obesity and, if untreated, can progress to cirrhosis.

Multiple clinical trials have examined the effect of GLP-1 medications on liver health. The consistent finding is that GLP-1 treatment reduces hepatic fat content and markers of liver inflammation. In 2024, the FDA approved a brand-name semaglutide product for the treatment of MASH, based on histological evidence of liver improvement (fibrosis stage reduction and resolution of steatohepatitis) in patients who received the medication.

If your provider has mentioned elevated liver enzymes, fatty liver, or has diagnosed MASH or NAFLD, GLP-1 treatment may be addressing more than weight. Read more: GLP-1 and Fatty Liver Disease.

Metabolic syndrome: the cluster that GLP-1 addresses directly

Metabolic syndrome is not a single disease – it is a cluster of conditions that frequently occur together: abdominal obesity, high blood pressure, high blood sugar, high triglycerides, and low HDL cholesterol. Having three or more of these criteria meets the clinical definition.

Each component of metabolic syndrome increases cardiovascular and diabetes risk. Together they compound each other. GLP-1 medications, by addressing insulin resistance, reducing appetite and caloric intake, and producing weight loss, tend to improve multiple components simultaneously. Triglycerides typically fall. Blood pressure often improves. Blood sugar trends in the right direction. Read more: GLP-1 and Metabolic Syndrome.

Other conditions in this section

The child pages in this section address additional populations and topics that the clinical evidence is beginning to inform:

Fertility. Weight-related hormonal disruption can affect ovulation and fertility in women with PCOS or obesity. GLP-1 treatment may improve fertility outcomes in some patients, though this is an area where provider guidance is important – the medication should generally be discontinued before trying to conceive. Read more: GLP-1 and Fertility.

Older adults. Patients over 60 have specific considerations around muscle mass preservation, bone density, and medication interactions. The evidence base for GLP-1 in older adults is growing, and the benefit-risk calculation differs from younger patients. Read more: GLP-1 for Older Adults Over 60.

Obesity prevalence data. If you are curious about obesity rates by county or state across the United States, the CDC publishes detailed county-level health data. We have assembled that information into an accessible format: Obesity by County: Health Data Map.

What’s in this section

Nine child pages go deeper on each condition:

• GLP-1 and Sleep Apnea – SURMOUNT-OSA trial findings and the 2024 FDA approval for obesity-related OSA.
• GLP-1 and Cardiovascular Health – The SELECT trial, 20% reduction in major cardiovascular events, and who qualifies.
• GLP-1 and Metabolic Syndrome – How GLP-1 addresses the cluster of conditions that define metabolic syndrome.
• GLP-1 and Fertility – Hormonal effects, PCOS overlap, and guidance on GLP-1 use when trying to conceive.
• GLP-1 for Older Adults Over 60 – Muscle preservation, bone density, and the specific considerations for patients over 60.
• GLP-1 and Fatty Liver Disease – The 2024 FDA approval for MASH and what the liver histology data shows.
• GLP-1 and Kidney Health: FLOW Trial – How the FLOW trial changed the evidence picture for CKD and GLP-1.
• Obesity by County: Health Data Map – CDC county-level obesity and metabolic health data.
• GLP-1 and PCOS: Insulin Resistance, Hormones, Weight Loss – How GLP-1 addresses the insulin resistance at the root of PCOS symptoms.

Back to the GLP-1 Patient Guide.